MEK1/2 blockade by AZD6244 (ARRY-142886) inhibits tumor growth and progression in an orthotopic human lung adenocarcinoma model with enhanced efficacy when combined with cediranib
Autori principali: | Takahashi, O, Komaki, R, Smith, P, Ryan, A, Jurgensmeier, J, Welsh, J, Jacoby, J, Hosho, K, Korshunova, M, Erez, B, Herbst, R, O'Reilly, MS |
---|---|
Natura: | Journal article |
Pubblicazione: |
2009
|
Documenti analoghi
Documenti analoghi
-
DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
di: Gupta, A, et al.
Pubblicazione: (2013) -
AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study
di: Dummer, R, et al.
Pubblicazione: (2008) -
Author Correction: Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer
di: Jin-Hang Gao, et al.
Pubblicazione: (2022-03-01) -
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
di: Takahashi, O, et al.
Pubblicazione: (2012) -
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis
di: Takahashi, O, et al.
Pubblicazione: (2012)